 Proactive Investors USA & Canada | Dynavax reports late stage drug trial, Q3 losses widen Proactive Investors USA & Canada The phase three study, which enrolled 507 patients aged 18 to 75 with chronic kidney disease, had been conducted at 69 sites in the US, Canada and Germany. According to the results, Heplisav demonstrated rapid protection with fewer doses than current ... Dynavax Phase 3 Data in Chronic Kidney Disease Demonstrates Superiority of ... Dynavax Phase 3 Data in Chronic Kidney Disease Demonstrates Superiority of ... Dynavax Technologies Corporation : Dynavax Confirms HEPLISAV(TM) Submission ... |
